Cargando…

Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()

OBJECTIVES: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jennifer H., Davis, Nicole L., Corbett, Amanda H., Chinula, Lameck, Cottrell, Mackenzie L., Zia, Yasaman, Tegha, Gerald, Stanczyk, Frank Z., Hurst, Stacey, Hosseinipour, Mina C., Haddad, Lisa B., Kourtis, Athena P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752709/
https://www.ncbi.nlm.nih.gov/pubmed/33364598
http://dx.doi.org/10.1016/j.conx.2020.100027
_version_ 1783625924321738752
author Tang, Jennifer H.
Davis, Nicole L.
Corbett, Amanda H.
Chinula, Lameck
Cottrell, Mackenzie L.
Zia, Yasaman
Tegha, Gerald
Stanczyk, Frank Z.
Hurst, Stacey
Hosseinipour, Mina C.
Haddad, Lisa B.
Kourtis, Athena P.
author_facet Tang, Jennifer H.
Davis, Nicole L.
Corbett, Amanda H.
Chinula, Lameck
Cottrell, Mackenzie L.
Zia, Yasaman
Tegha, Gerald
Stanczyk, Frank Z.
Hurst, Stacey
Hosseinipour, Mina C.
Haddad, Lisa B.
Kourtis, Athena P.
author_sort Tang, Jennifer H.
collection PubMed
description OBJECTIVES: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. STUDY DESIGN: We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. RESULTS: The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46–0.79] at 1 month to 0.27 (90% CI 0.12–0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy). CONCLUSIONS: Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users. IMPLICATIONS: Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.
format Online
Article
Text
id pubmed-7752709
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77527092020-12-23 Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()() Tang, Jennifer H. Davis, Nicole L. Corbett, Amanda H. Chinula, Lameck Cottrell, Mackenzie L. Zia, Yasaman Tegha, Gerald Stanczyk, Frank Z. Hurst, Stacey Hosseinipour, Mina C. Haddad, Lisa B. Kourtis, Athena P. Contracept X Original research OBJECTIVES: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. STUDY DESIGN: We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. RESULTS: The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46–0.79] at 1 month to 0.27 (90% CI 0.12–0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy). CONCLUSIONS: Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users. IMPLICATIONS: Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up. Elsevier 2020-05-29 /pmc/articles/PMC7752709/ /pubmed/33364598 http://dx.doi.org/10.1016/j.conx.2020.100027 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original research
Tang, Jennifer H.
Davis, Nicole L.
Corbett, Amanda H.
Chinula, Lameck
Cottrell, Mackenzie L.
Zia, Yasaman
Tegha, Gerald
Stanczyk, Frank Z.
Hurst, Stacey
Hosseinipour, Mina C.
Haddad, Lisa B.
Kourtis, Athena P.
Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title_full Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title_fullStr Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title_full_unstemmed Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title_short Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
title_sort effect of efavirenz on levonorgestrel concentrations among malawian levonorgestrel implant users for up to 30 months of concomitant use: a subanalysis of a randomized clinical trial()()
topic Original research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752709/
https://www.ncbi.nlm.nih.gov/pubmed/33364598
http://dx.doi.org/10.1016/j.conx.2020.100027
work_keys_str_mv AT tangjenniferh effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT davisnicolel effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT corbettamandah effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT chinulalameck effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT cottrellmackenziel effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT ziayasaman effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT teghagerald effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT stanczykfrankz effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT hurststacey effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT hosseinipourminac effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT haddadlisab effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial
AT kourtisathenap effectofefavirenzonlevonorgestrelconcentrationsamongmalawianlevonorgestrelimplantusersforupto30monthsofconcomitantuseasubanalysisofarandomizedclinicaltrial